Photo from wikipedia
30 [76.7%] versus 125 of 214 [58.4%]). Requests for OLU for lymphoma patients were less frequently rejected by health insurers (3 of 30 [10.0%] versus 64 of 214 [29.9%]). In… Click to show full abstract
30 [76.7%] versus 125 of 214 [58.4%]). Requests for OLU for lymphoma patients were less frequently rejected by health insurers (3 of 30 [10.0%] versus 64 of 214 [29.9%]). In two cases, OLU of the same drug and the same lymphoma therapy indication was approved by one health insurer for reimbursement but rejected by another. Conclusion: In Switzerland, off-label use seems to be more frequent in lymphoma patients than in patients with solid tumors. Their chances for reimbursement of OLU also seem to be higher. However, reimbursement decisions seem to be inconsistent, which reflects intransparency of the current decision making process on OLU reimbursement requests by health insurers. Reasons for these differences remain to be elucidated and further data will be presented at the meeting.
Journal Title: Hematological Oncology
Year Published: 2019
Link to full text (if available)
Share on Social Media: Sign Up to like & get
recommendations!